(NASDAQ:GLTO), DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Recent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical Officer Pipeline of additional candidates advancing to the […]

(NasdaqGM:ENPH), FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, today announced that it began production shipments of its IQ9N-3P(TM) Commercial Microinverter across the United States in late December 2025. The product is manufactured in the United States to support domestic content requirements and Foreign Entity

(NASDAQ:HYPD), LAGUNA HILLS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”) today issued a letter to shareholders from its Chief Executive Officer, Hyunsu Jung. To the shareholders of Hyperion DeFi, Inc.: Let me start by expressing my sincere gratitude to those sharing in our journey to

(NASDAQ:ZM), SAN JOSE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — As artificial intelligence (AI) becomes a foundational skill for the future workforce, Zoom Communications, Inc. (NASDAQ: ZM) is reinforcing its commitment to AI literacy with Zoom Ahead: AI for Tomorrow's Leaders. This live national learning experience is designed to help students understand how AI can

TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) — Support staff for the Elementary Teachers' Federation of Ontario will hit the picket lines at 136 Isabella Street in Toronto this morning. The workers are members of SEIU Local 2 and say ETFO is not treating them with respect and fairness. At issue are wages and paid leave.

(NasdaqGM:CNTB), – Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart – – Recruitment ongoing for Phase 1b study of intravenously-administered rademikibart designed to further confirm its unique ability to rapidly improve airway function with topline results expected in first quarter 2026 – – Recruitment ongoing for Phase 2

(NasdaqGM:BCAX), Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to achieve substantial enrollment in FORTIFI-HN01 in 2026 to enable interim analysis in mid-2027 Anticipates multiple expansion cohort data readouts in 2026 to further characterize ficerafusp alfa's profile in

(NASDAQ:KYTX), Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026 First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis (gMG) Completed follow-on offering extends cash runway into 2028, expected to fully fund SPS BLA filing, commercial launch, and Phase

(NASDAQ:CVRX), Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5% Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11% Fiscal 2026 revenue expected to be between $63 million and $67 million, representing growth of 11% to 18% Category I

— Study highlights importance of cancer driver biology in translating results from lab to patients — — Findings validate proprietary OncoSLX Platform(TM), a pharmacogenetic approach that captures the full spectrum of drug biology — — Continuing to advance lead asset LFB190, a BET inhibitor, targeting EP300 lossâ€'ofâ€'function cancers; expect to initiate Phase 1b/2a clinical trial